1AD Share Price Performance
AU$0
-0.00 (-100.00%)
Price AU$0
Share Pricen/a
AdAlta Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
1AD Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
AdAlta Limited Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.0015
- 32.05%
- -1,158.67%
- 0%
About 1AD
- Founded
- 2006
- Employees
- 2
- CEO
- WebsiteView website
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.
